Skip to main content

Congratulations Dr. Shami

Dr. Paul Shami and JSK Therapeutics were granted an award from the Small Business Innovation Research Program of the National Cancer Institute to conduct IND-enabling studies of their nitric oxide-generating drug JS-K. JS-K has shown efficacy in animal models of acute myeloid leukemia, multiple myeloma, non-small cell lung cancer and several other solid tumors. Completion of work conducted with this award will allow initiation of Phase I clinical trials of this first-in-class anti-cancer agent. Congratulations to Dr. Shami and his team for this Direct-to-Phase II SBIR award.